307307-97-7

Basic information

• Product Name: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-
• Synonyms: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-;4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid;4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid(SALTDATA: FREE);4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxylic acid
• CAS NO: 307307-97-7
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• Mol File: 307307-97-7.mol

Chemical Properties

• Boiling Point: 376.713 °C at 760 mmHg
• Flash Point: 181.63 °C
• Appearance: White/Crystalline Powder
• Density: 1.454g/cm³
• PKA: 3.89±0.20(Predicted)
• CAS DataBase Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-(307307-97-7)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-(307307-97-7)

Safety Data

• Hazardous Substances Data: 307307-97-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydrois used as a building block or intermediate in the synthesis of medicinal drugs due to its potential biological activity. Its presence in the complex pyrazolopyridine category suggests that it may contribute to the development of new therapeutic agents with various pharmacological effects.

Upstream product

• 105786-95-6 4,5,6,7-tetrahydro<1.2.3>oxadiazolo<3,4-a>pyridin-3-one 
• 118055-06-4 4,5,6,7-Tetrahydropyrazolo<1,5-a>pyridin-3-carbonsaeureethylester 
• 4043-87-2 pipecolic Acid 

Downstream Products

• 1367714-09-7 C₂₀H₂₄F₂N₄O 

Relevant articles and documents

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Identification of fused bicyclic heterocycles as potent and selective 5-HT2A receptor antagonists for the treatment of insomnia

A series of fused bicyclic heterocycles was identified as potent and selective 5-HT2A receptor antagonists. Optimization of the series resulted in compounds that had improved PK properties, favorable CNS partitioning, good pharmacokinetic properties, and significant improvements on deep sleep (delta power) and sleep consolidation.